. >> host: well kind well, kind of belief that eli lilly, esther seneca's they have put all of this money into research coming to finding a cure, problem ask, they should have the right to market and to sell that product. >> certainly. that is an argument that has no shortage of people advancing it. if if you look at the way generic drug policy has been driven this is the basis of the monopoly. we create things to manipulatives. and generic drugs the faster. and one way of looking at it one of the things that compelled me a lot of writing this book is realizing that we have come to accept as natural a two-part lifecycle approach to how does work. an innovative company like eli lilly, pfizer, they invest a lot of money in r&d so very much part of the lifecycle available high price. innovation at the cost of access. and then at the end of the patent live we have generic competition to assume that if more is more and more competitors commend the price will come down which emphasizes access. access over innovation. at tuesday's lifecycle is probably the result of a broad handshake. wax hatch